Hydroxychloroquine retinopathy: is screening necessary?
作者信息
Blyth C, Lane C
出版信息
BMJ. 1998 Mar 7;316(7133):716-7. doi: 10.1136/bmj.316.7133.716.
Abstract
摘要
相似文献
1
Hydroxychloroquine retinopathy: is screening necessary?羟氯喹视网膜病变：是否需要筛查？
BMJ. 1998 Mar 7;316(7133):716-7. doi: 10.1136/bmj.316.7133.716.
2
Hydroxychloroquine retinopathy.羟氯喹视网膜病变
Arch Ophthalmol. 1999 Sep;117(9):1262-3. doi: 10.1001/archopht.117.9.1262.
3
Blurred vision: targeting a diagnosis.
BMJ. 2013 Sep 12;347:f5209. doi: 10.1136/bmj.f5209.
4
Should patients on hydroxychloroquine have their eyes examined regularly?服用羟氯喹的患者需要定期检查眼睛吗？
Br J Rheumatol. 1997 May;36(5):514-5. doi: 10.1093/rheumatology/36.5.514.
5
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.氯喹与羟氯喹疗效及安全性的眼科视角
J Rheumatol. 1999 Sep;26(9):1866-8.
6
[SD-OCT As screening test for hydroxychloroquine retinopathy: The «flying saucer» sign].[频域光学相干断层扫描作为羟氯喹视网膜病变的筛查试验：“飞碟”征]
Arch Soc Esp Oftalmol. 2015 Jul;90(7):338-40. doi: 10.1016/j.oftal.2014.03.020. Epub 2014 Nov 15.
7
Missing the bull's eye.未中靶心。
Surv Ophthalmol. 2007 Jul-Aug;52(4):440-2. doi: 10.1016/j.survophthal.2007.04.001.
8
New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy.美国眼科学会关于羟氯喹视网膜病变筛查的新建议。
Arthritis Rheum. 2003 Jun;48(6):1764. doi: 10.1002/art.10980.
9
Early macular toxicity following 2 months of hydroxychloroquine therapy.羟氯喹治疗2个月后的早期黄斑毒性。
Arch Soc Esp Oftalmol (Engl Ed). 2018 Mar;93(3):e20-e21. doi: 10.1016/j.oftal.2017.12.004. Epub 2018 Feb 1.
10
The gathering storm: hydroxychloroquine retinopathy screening in the U.K.即将到来的风暴：英国的羟氯喹视网膜病变筛查
Br J Dermatol. 2017 Jun;176(6):1420-1421. doi: 10.1111/bjd.15567.
引用本文的文献
1
Ocular Side Effects of Systemic Drugs Used in Dermatology.皮肤科常用全身性药物的眼部副作用
Indian J Dermatol. 2019 Nov-Dec;64(6):423-430. doi: 10.4103/ijd.IJD_353_18.
2
Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.氯喹和羟氯喹所致的眼毒性：电生理与视觉功能的相关性
Doc Ophthalmol. 2005 Jan;110(1):111-20. doi: 10.1007/s10633-005-7349-6.
3
Screening for hydroxychloroquine retinopathy. Screening should be selective.羟氯喹视网膜病变的筛查。筛查应具有选择性。
BMJ. 1998 Nov 14;317(7169):1388-9. doi: 10.1136/bmj.317.7169.1388a.
本文引用的文献
1
Retinopathy following chloroquine therapy.氯喹治疗后的视网膜病变。
Lancet. 1959 Oct 3;2(7101):478-80. doi: 10.1016/s0140-6736(59)90604-x.
2
Retinal toxicity in long term hydroxychloroquine treatment.长期使用羟氯喹治疗中的视网膜毒性
Ann Rheum Dis. 1996 Mar;55(3):187-9. doi: 10.1136/ard.55.3.187.
3
Hydroxychloroquine, dosage parameters and retinopathy.
Lupus. 1993 Dec;2(6):355-8. doi: 10.1177/096120339300200604.
4
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.抗疟药用于类风湿关节炎长期治疗时的剂量调整
Am J Med. 1983 Jul 18;75(1A):40-5. doi: 10.1016/0002-9343(83)91269-x.
5
The sensitivity of Amsler grid testing in early chloroquine retinopathy.阿姆斯勒方格表检查在早期氯喹视网膜病变中的敏感性
Trans Ophthalmol Soc U K (1962). 1985;104 ( Pt 2):204-7.
6
Screening for hydroxychloroquine retinal toxicity: is it necessary?
Eye (Lond). 1990;4 ( Pt 4):572-6. doi: 10.1038/eye.1990.79.
7
Ocular safety of hydroxychloroquine.羟氯喹的眼部安全性。
Ann Ophthalmol. 1991 Aug;23(8):292-6.
Zotero 插件